focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,078.00
Bid: 12,894.00
Ask: 9,733.00
Change: -88.00 (-0.72%)
Spread: -3,161.00 (-24.515%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

European shares rise tentatively

Fri, 23rd Dec 2022 09:43

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

EUROPEAN SHARES RISE TENTATIVELY (0915 GMT)

European indices are enjoying a moderate lift this morning, as the STOXX 600 ticked up in the first hour of trading and is now around 0.28% higher.

The top riser of the index is Danish biotech Bavarian Nordic, with shares up 5.8% after the company said it had signed a deal worth up to $83 million with the U.S Department of Defense.

Swiss drugmaker Roche Holding is providing the biggest lift on a weighted basis, while French luxury company LVMH is one of the larger drags, along with ASML , Nestle and

Retail is the sector outperformer, up 0.7%, while travel and leisure and utilities are the worst off, down 0.1%-0.2%.

GRINCH (RE)APPEARS (0744 GMT)

Ignoring a hawkish Fed, investors attempted the briefest of Santa rallies this week but revised U.S. GDP data and relatively low claims for unemployment benefits have brought back worries of higher-for-longer interest rates.

And so the safe-haven U.S. dollar is back on the prowl, with Asian shares set to end in the red for a second straight week.

Investors will now focus on U.S. personal consumption expenditures data, due later on Friday, which will provide more clues on the direction of inflation as traders look ahead to 2023.

Some are clinging to the hope that central banks will likely pause interest rate hikes next year in the face of an economic slowdown.

But as Generali Investments strategists put it, central banks are still showing their teeth, committed to tackling inflation, and an outright policy pivot looks distant.

The yen managed to retain most of its gains against the dollar after the BOJ bombshell earlier this week, with data on Friday showing that Japan's consumer inflation hit a fresh 40-year high, adding to pressure on the central bank to alter its ultra-easy policy.

Meanwhile, COVID-19 infections in China are likely to hit their peak within a week, a health official said, as China's health system prepares for a surge in cases weeks after the country began dismantling its zero-COVID policy.

The saga around the collapse of the FTX crypto exchange rumbles on, with Sam Bankman-Fried released on a $250 million bond package while he awaits trial.

In the corporate world, chip stocks slumped worldwide after Micron's dour forecast on what the chipmaker called a "significant supply demand mismatch".

Tesla CEO and Twitter owner Elon Musk said he will not sell any more Tesla stock for about two years, as the EV maker's stock is on track for its worst-ever monthly performance.

Key developments that could influence markets on Friday:

Economic events: Spain Q3 GDP data, France November producer price data

'TIS THE SEASON AFTER ALL (0734 GMT)

European futures are rising around 0.3%, with the STOXX 600 set to wrap up the last week before Christmas in the green.

The London Stock Exchange will begin a market closing process from 1230 GMT today. European bourses remain open all day, barring Dublin, which also has a half day.

Though the index has added 0.59% since Monday, it is no where near enough to reverse the 3.2% drop last week amid a spate of central bank decisions and business activity data that pointed to a slowdown in growth.

The index remains 12.4% lower than where it started the year.

Attention is staying on China, which expects a peak in COVID-19 infections within a week, and on Japan, where the latest data showed core consumer inflation hitting a four-decade high.

Minutes on Friday showed Bank of Japan (BOJ) policymakers had discussed the potential market impact of a future exit from ultra-low interest rates, months before a surprise tweak to its yield control policy earlier this week.

More News
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 09:41

LONDON BROKER RATINGS: Deutsche Bank starts Deliveroo at 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
12 Feb 2024 09:12

Barclays sees "compelling" entry point at AstraZeneca after recent falls

(Sharecast News) - Barclays has kept an 'overweight' position on AstraZeneca despite the biopharma group's disappointing annual results last week, saying that the stock's recent underperformance provides an attractive entry point for investors.

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.